伊維菌素 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "伊維菌素" in Chinese language version.

refsWebsite

Global rank Chinese rank

25web.archive.org

1^st place

14nih.gov

4^th place

5^th place

11doi.org

2^nd place

23^rd place

5google.co.jp

934^th place

984^th place

3worldcat.org

5^th place

12^th place

2drugs.com

399^th place

208^th place

2pebmed.com.br

low place

2who.int

195^th place

179^th place

1msh.org

low place

2,351^st place

1archive.org

6^th place

4^th place

1acs.org

1,248^th place

434^th place

1nobelprize.org

301^st place

262^nd place

1jamanetwork.com

2,650^th place

1,976^th place

1uto.edu.bo

low place

1bmj.com

1,226^th place

890^th place

1fda.gov

447^th place

581^st place

1bbc.co.uk

8^th place

32^nd place

1oup.com

485^th place

489^th place

1sciencebasedmedicine.org

5,063^rd place

low place

1merck.com

6,464^th place

3,752^nd place

1semanticscholar.org

11^th place

332^nd place

1europa.eu

68^th place

209^th place

1infectologia.org.br

low place

acs.org

pubs.acs.org

W. C. CAMPBELL; R. W. BURG, , M. H. FISHER, and , R. A. DYBAS. The Discovery of Ivermectin and Other Avermectins. American Chemical Society: 5–20. 1984-06-26 [2015-10-09]. ISBN 9780841210837. （原始内容存档于2019-06-01）. |chapter=被忽略 (帮助)

archive.org

Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 1992, 32: 537–53. PMID 1605577. doi:10.1146/annurev.pa.32.040192.002541.

bbc.co.uk

Schraer, Rachel. Covid: Ivermectin to be studied as possible treatment in UK. BBC News. 23 June 2021 [23 June 2021]. （原始内容存档于2021-07-20）.

bmj.com

ebm.bmj.com

Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine. 2021-04-22 [2021-07-11]. ISSN 2515-446X. PMID 33888547. doi:10.1136/bmjebm-2021-111678 . （原始内容存档于2021-05-28）.

doi.org

dx.doi.org

Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 1992, 32: 537–53. PMID 1605577. doi:10.1146/annurev.pa.32.040192.002541.
Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. September 2020, 73 (9): 593–602. PMC 7290143 . PMID 32533071. doi:10.1038/s41429-020-0336-z.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. April 2020, 178: 104787. PMC 7129059 . PMID 32251768. doi:10.1016/j.antiviral.2020.104787.
Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences. April 2020, 50 (SI-1): 611–619. PMC 7195979 . PMID 32293834. doi:10.3906/sag-2004-145 .
Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Research. June 2020, 178: 104805. PMC 7172803 . PMID 32330482. doi:10.1016/j.antiviral.2020.104805.
López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）. 已忽略未知参数|pmc-embargo-date= (帮助)
Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer (PDF). Antiviral Research. May 2020, 177: 104760 [2021-07-11]. PMID 32135219. doi:10.1016/j.antiviral.2020.104760. （原始内容存档 (PDF)于2020-07-13）.
Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine. 2021-04-22 [2021-07-11]. ISSN 2515-446X. PMID 33888547. doi:10.1136/bmjebm-2021-111678 . （原始内容存档于2021-05-28）.
Bartoszko JJ, Siemieniuk RA, Kum E, Qasim A, Zeraatkar D, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ (Systematic review). April 2021, 373: n949. PMC 8073806 . PMID 33903131. doi:10.1136/bmj.n949.
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 28 June 2021 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.
Wadvalla BA. Covid-19: Ivermectin's politicisation is a warning sign for doctors turning to orphan treatments. BMJ. April 2021, 373: n747. PMID 33795225. S2CID 232484313. doi:10.1136/bmj.n747 .

drugs.com

Ivermectin. The American Society of Health-System Pharmacists. [Jan 2016]. （原始内容存档于2016-01-03）.
Ivermectin Levels and Effects while Breastfeeding. [2016-01-16]. （原始内容存档于2016-01-01）.

europa.eu

ema.europa.eu

EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials (新闻稿). European Medicines Agency. 22 March 2021 [2021-07-11]. （原始内容存档于2021-08-04）.

fda.gov

Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. U.S. Food and Drug Administration (FDA). 5 March 2021 [5 March 2021]. （原始内容存档于2021-08-06）.

google.co.jp

books.google.co.jp

Saunders Handbook of Veterinary Drugs: Small and Large Animal 4. Elsevier Health Sciences. 2015: 420 [2016-01-24]. ISBN 9780323244862. （原始内容存档于2016-01-31）.
Sneader, Walter. Drug Discovery a History.. Chichester: John Wiley & Sons. 2005: 333 [2016-01-24]. ISBN 9780470015520. （原始内容存档于2016-01-31）.
Hamilton, Richard J. Tarascon pocket pharmacopoeia : 2014 deluxe lab-pocket edition 15th edition. Sudbury: Jones & Bartlett Learning. 2014: 422 [2016-01-24]. ISBN 9781284053999. （原始内容存档于2016-01-31）.
Mehlhorn, Heinz. Encyclopedia of parasitology 3rd ed. Berlin: Springer. 2008: 646 [2016-01-24]. ISBN 9783540489948. （原始内容存档于2016-01-31）.
Vercruysse, edited by J.; Rew, R.S. Macrocyclic lactones in antiparasitic therapy. Oxon, UK: CABI Pub. 2002: Preface [2016-01-24]. ISBN 9780851998404. （原始内容存档于2016-01-31）.

infectologia.org.br

Atualizações e Recomendações sobre a Covid-19 [Updates and recommendations on Covid-19] (PDF). Sociedade Brasileira de Infectologia. 2020-12-09 [2021-07-11]. （原始内容存档 (PDF)于2021-03-22）（葡萄牙语）.

jamanetwork.com

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）. 已忽略未知参数|pmc-embargo-date= (帮助)

merck.com

Merck Statement on Ivermectin use During the COVID-19 Pandemic. Merck. 4 February 2021 [2021-07-11]. （原始内容存档于2021-08-03）.

msh.org

erc.msh.org

Ivermectin. International Drug Price Indicator Guide. [2016-01-16]. ^{[永久失效連結]}

nih.gov

ncbi.nlm.nih.gov

Panahi, Y; Poursaleh, Z; Goldust, M. The efficacy of topical and oral ivermectin in the treatment of human scabies.. Annals of parasitology. 2015, 61 (1): 11–6. PMID 25911032.
Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 1992, 32: 537–53. PMID 1605577. doi:10.1146/annurev.pa.32.040192.002541.
Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. September 2020, 73 (9): 593–602. PMC 7290143 . PMID 32533071. doi:10.1038/s41429-020-0336-z.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. April 2020, 178: 104787. PMC 7129059 . PMID 32251768. doi:10.1016/j.antiviral.2020.104787.
Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences. April 2020, 50 (SI-1): 611–619. PMC 7195979 . PMID 32293834. doi:10.3906/sag-2004-145 .
Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Research. June 2020, 178: 104805. PMC 7172803 . PMID 32330482. doi:10.1016/j.antiviral.2020.104805.
López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）. 已忽略未知参数|pmc-embargo-date= (帮助)
Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer (PDF). Antiviral Research. May 2020, 177: 104760 [2021-07-11]. PMID 32135219. doi:10.1016/j.antiviral.2020.104760. （原始内容存档 (PDF)于2020-07-13）.
Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine. 2021-04-22 [2021-07-11]. ISSN 2515-446X. PMID 33888547. doi:10.1136/bmjebm-2021-111678 . （原始内容存档于2021-05-28）.
Bartoszko JJ, Siemieniuk RA, Kum E, Qasim A, Zeraatkar D, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ (Systematic review). April 2021, 373: n949. PMC 8073806 . PMID 33903131. doi:10.1136/bmj.n949.
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 28 June 2021 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.
Wadvalla BA. Covid-19: Ivermectin's politicisation is a warning sign for doctors turning to orphan treatments. BMJ. April 2021, 373: n747. PMID 33795225. S2CID 232484313. doi:10.1136/bmj.n747 .

nih.gov

COVID-19 Therapeutics Prioritized for Testing in Clinical Trials. National Institutes of Health. [27 June 2021]. （原始内容存档于2021-08-05）.

covid19treatmentguidelines.nih.gov

The COVID-19 Treatment Guidelines Panel's Statement on the Use of Ivermectin for the Treatment of COVID-19. National Institutes of Health. 14 January 2020 [2021-07-11]. （原始内容存档于2021-02-08）.

nobelprize.org

The Nobel Prize in Physiology or Medicine 2015. Nobel Foundation. [2020-05-06]. （原始内容存档于2021-02-09）.

oup.com

academic.oup.com

Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 28 June 2021 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.

pebmed.com.br

Quintanilha, Dayana de Oliveira. Anvisa se manifesta contra o uso da ivermectina na Covid-19 [Anvisa speaks out against the use of ivermectin in Covid-19]. PEBMED. 2020-07-13 [2021-07-11]. （原始内容存档于2021-07-12）（葡萄牙语）.
Posicionamento da Sociedade Brasileira de Pneumologia e Tisiologia Sobre o Colapso em Manaus e Tratamento Preventivo e Precoce da Covid-19 [Brazilian Thoracic Society Position Statement on the Collapse in Manaus and the Preventive and Early Treatment of Covid-19]. Sociedade Brasileira de Pneumologia e Tisiologia. 2021-01-17 [2021-01-18]. （原始内容存档于2021-07-12）（葡萄牙语）.

sciencebasedmedicine.org

Gorski DH. Ivermectin is the new hydroxychloroquine. Science-Based Medicine. 15 April 2021 [2021-07-11]. （原始内容存档于2021-07-12）.

semanticscholar.org

api.semanticscholar.org

Wadvalla BA. Covid-19: Ivermectin's politicisation is a warning sign for doctors turning to orphan treatments. BMJ. April 2021, 373: n747. PMID 33795225. S2CID 232484313. doi:10.1136/bmj.n747 .

uto.edu.bo

dicyt.uto.edu.bo

Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer (PDF). Antiviral Research. May 2020, 177: 104760 [2021-07-11]. PMID 32135219. doi:10.1016/j.antiviral.2020.104760. （原始内容存档 (PDF)于2020-07-13）.

web.archive.org

Ivermectin. The American Society of Health-System Pharmacists. [Jan 2016]. （原始内容存档于2016-01-03）.
Saunders Handbook of Veterinary Drugs: Small and Large Animal 4. Elsevier Health Sciences. 2015: 420 [2016-01-24]. ISBN 9780323244862. （原始内容存档于2016-01-31）.
Sneader, Walter. Drug Discovery a History.. Chichester: John Wiley & Sons. 2005: 333 [2016-01-24]. ISBN 9780470015520. （原始内容存档于2016-01-31）.
Hamilton, Richard J. Tarascon pocket pharmacopoeia : 2014 deluxe lab-pocket edition 15th edition. Sudbury: Jones & Bartlett Learning. 2014: 422 [2016-01-24]. ISBN 9781284053999. （原始内容存档于2016-01-31）.
Mehlhorn, Heinz. Encyclopedia of parasitology 3rd ed. Berlin: Springer. 2008: 646 [2016-01-24]. ISBN 9783540489948. （原始内容存档于2016-01-31）.
Ivermectin Levels and Effects while Breastfeeding. [2016-01-16]. （原始内容存档于2016-01-01）.
Vercruysse, edited by J.; Rew, R.S. Macrocyclic lactones in antiparasitic therapy. Oxon, UK: CABI Pub. 2002: Preface [2016-01-24]. ISBN 9780851998404. （原始内容存档于2016-01-31）.
WHO Model List of Essential Medicines (PDF). World Health Organization. October 2013 [2014-04-22]. （原始内容存档 (PDF)于2014-04-23）.
W. C. CAMPBELL; R. W. BURG, , M. H. FISHER, and , R. A. DYBAS. The Discovery of Ivermectin and Other Avermectins. American Chemical Society: 5–20. 1984-06-26 [2015-10-09]. ISBN 9780841210837. （原始内容存档于2019-06-01）. |chapter=被忽略 (帮助)
The Nobel Prize in Physiology or Medicine 2015. Nobel Foundation. [2020-05-06]. （原始内容存档于2021-02-09）.
López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）. 已忽略未知参数|pmc-embargo-date= (帮助)
Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer (PDF). Antiviral Research. May 2020, 177: 104760 [2021-07-11]. PMID 32135219. doi:10.1016/j.antiviral.2020.104760. （原始内容存档 (PDF)于2020-07-13）.
Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine. 2021-04-22 [2021-07-11]. ISSN 2515-446X. PMID 33888547. doi:10.1136/bmjebm-2021-111678 . （原始内容存档于2021-05-28）.
Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. U.S. Food and Drug Administration (FDA). 5 March 2021 [5 March 2021]. （原始内容存档于2021-08-06）.
Schraer, Rachel. Covid: Ivermectin to be studied as possible treatment in UK. BBC News. 23 June 2021 [23 June 2021]. （原始内容存档于2021-07-20）.
COVID-19 Therapeutics Prioritized for Testing in Clinical Trials. National Institutes of Health. [27 June 2021]. （原始内容存档于2021-08-05）.
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 28 June 2021 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.
Gorski DH. Ivermectin is the new hydroxychloroquine. Science-Based Medicine. 15 April 2021 [2021-07-11]. （原始内容存档于2021-07-12）.
Merck Statement on Ivermectin use During the COVID-19 Pandemic. Merck. 4 February 2021 [2021-07-11]. （原始内容存档于2021-08-03）.
The COVID-19 Treatment Guidelines Panel's Statement on the Use of Ivermectin for the Treatment of COVID-19. National Institutes of Health. 14 January 2020 [2021-07-11]. （原始内容存档于2021-02-08）.
EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials (新闻稿). European Medicines Agency. 22 March 2021 [2021-07-11]. （原始内容存档于2021-08-04）.
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. World Health Organisation. 31 March 2021 [2021-07-11]. （原始内容存档于2021-08-05）.
Quintanilha, Dayana de Oliveira. Anvisa se manifesta contra o uso da ivermectina na Covid-19 [Anvisa speaks out against the use of ivermectin in Covid-19]. PEBMED. 2020-07-13 [2021-07-11]. （原始内容存档于2021-07-12）（葡萄牙语）.
Atualizações e Recomendações sobre a Covid-19 [Updates and recommendations on Covid-19] (PDF). Sociedade Brasileira de Infectologia. 2020-12-09 [2021-07-11]. （原始内容存档 (PDF)于2021-03-22）（葡萄牙语）.
Posicionamento da Sociedade Brasileira de Pneumologia e Tisiologia Sobre o Colapso em Manaus e Tratamento Preventivo e Precoce da Covid-19 [Brazilian Thoracic Society Position Statement on the Collapse in Manaus and the Preventive and Early Treatment of Covid-19]. Sociedade Brasileira de Pneumologia e Tisiologia. 2021-01-17 [2021-01-18]. （原始内容存档于2021-07-12）（葡萄牙语）.

who.int

apps.who.int

WHO Model List of Essential Medicines (PDF). World Health Organization. October 2013 [2014-04-22]. （原始内容存档 (PDF)于2014-04-23）.

who.int

WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. World Health Organisation. 31 March 2021 [2021-07-11]. （原始内容存档于2021-08-05）.

worldcat.org

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）. 已忽略未知参数|pmc-embargo-date= (帮助)
Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine. 2021-04-22 [2021-07-11]. ISSN 2515-446X. PMID 33888547. doi:10.1136/bmjebm-2021-111678 . （原始内容存档于2021-05-28）.
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 28 June 2021 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.